Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial

PURPOSE: This phase 1 trial evaluated the safety, preliminary efficacy, and pharmacokinetics of surufatinib, a small molecular tyrosine kinase inhibitor, combined with toripalimab, a programmed cell death protein-1 antibody, in patients with advanced solid tumors. METHODS: This is an open-label, dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yanshuo, Lu, Ming, Sun, Yu, Gong, Jifang, Li, Jie, Lu, Zhihao, Li, Jian, Zhang, Xiaotian, Li, Yan, Peng, Zhi, Zhou, Jun, Wang, Xicheng, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931771/
https://www.ncbi.nlm.nih.gov/pubmed/35166929
http://dx.doi.org/10.1007/s00432-021-03898-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931771/
https://www.ncbi.nlm.nih.gov/pubmed/35166929
http://dx.doi.org/10.1007/s00432-021-03898-8

Ejemplares similares